

## Corrigendum

# High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma

**R Maréchal, P Demetter, N Nagy, A Berton, C Decaestecker, M Polus, J Closset, J Devière, I Salmon and J-L Van Laethem**

*British Journal of Cancer* (2010) **103**, 930. doi:10.1038/sj.bjc.6605894 www.bjcancer.com  
© 2010 Cancer Research UK

**Correction to:** *British Journal of Cancer* (2009) **100**, 1444–1451. doi:10.1038/sj.bjc.6605020

Upon publication of this paper in 2009, the authors noticed two errors – one in the abstract and one within the Results section.

On page 1444 (Abstract), the seventh sentence should read as follows:

'In a combining analysis, patients with a CXCR7<sup>high</sup>/CXCR4<sup>high</sup> tumour had a significantly shorter DFS and OS than patients with a CXCR4<sup>low</sup>/CXCR7<sup>low</sup> tumour'.

On page 1447 (Results), the first sentence of the section entitled 'CXCR4 and CXCR7 coexpression and patients outcome' should read as follows:

'Interestingly, patients with CXCR4<sup>low</sup>/CXCR7<sup>low</sup> tumour expression have a significantly prolonged DFS and OS than those patients with a CXCR4<sup>high</sup>/CXCR7<sup>high</sup> tumour expression (Figure 3C; median DFS: 15.80 months (95% CI: 10.43–21.17) vs 7.62 (2.97–12.27),  $P=0.037$ ; median OS: not reached vs 9.69 (95% CI: 5.13–14.07),  $P=0.001$ )'.